

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-178)

VIPIVOTIDE TETRAXETAN

PRONUNCIATION

vye piv' oh tide te trax' e tan


THERAPEUTIC CLAIM

Treatment of and imaging agent for prostate cancer

CHEMICAL NAMES

1. L-Lysine, *N*²-[[[(1*S*)-1,3-dicarboxypropyl]amino]carbonyl]-*N*⁶-[3-(2-naphthalenyl)-*N*-[[*trans*-4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]methyl]cyclohexyl]carbonyl]-L-alanyl]-
2. *N*²-[[[(1*S*)-1,3-Dicarboxypropyl]amino]carbonyl]-*N*⁶-[3-(2-naphthalenyl)-*N*-[[*trans*-4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]methyl]cyclohexyl]carbonyl]-L-alanyl]-L-lysine

STRUCTURAL FORMULA



MOLECULAR FORMULA

C₄₉ H₇₁ N₉ O₁₆

MOLECULAR WEIGHT

1042.1

TRADEMARK

None as yet

SPONSOR

Endocyte, Inc.

CODE DESIGNATIONS

PSMA-617

CAS REGISTRY NUMBER

1702967-37-0

UNII

4YM1W0EGQ5

WHO NUMBER

11010

SCS